Insulin resistance, renal dysfunction and cardiovascular disease, studies in a high and a low risk population by Oterdoom, Leendert Harmen
  
 University of Groningen
Insulin resistance, renal dysfunction and cardiovascular disease, studies in a high and a low
risk population
Oterdoom, Leendert Harmen
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2008
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Oterdoom, L. H. (2008). Insulin resistance, renal dysfunction and cardiovascular disease, studies in a high
and a low risk population. s.n.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
95
Fasting insulin is a stronger 
cardiovascular risk factor 
in women than in men
Leendert H Oterdoom, Aiko PJ de Vries, Ron T Gansevoort, 
Paul E de Jong, Reinold OB Gans and Stephan JL Bakker
Atherosclerosis 2008
chapter 6




Diabetes is a stronger risk factor for cardiovascular disease (cvd) in women 
than in men. It is not known whether there is also a sex difference in the 
association between hyperinsulinaemia, reflecting insulin resistance, and 
cvd.
Research design and methods
Fasting insulin was assessed with a specific assay in 6916 fasting, non-
diabetic subjects of the prevend study without a prior history of cvd. 
Major Adverse Cardiovascular Events (mace) (defined as cvd morbidity 
and cvd mortality) were prospectively recorded after the baseline survey. 
Cox regression models were used to investigate the association of fasting 
insulin with subsequent development of mace. 
Results
Fasting insulin was 54 [38-77] pmol/l in women (age 48 ± 12 yrs) and 57 
[40-88] pmol/l in men (age 49 ± 13 yrs). During follow-up for 7.5 [6.9-7.8] 
yr, 98 cardiovascular events were recorded in 3626 women and 242 events 
in 3290 men. There was a significant (P<0.001) interaction between sex 
and fasting insulin for mace, with the strongest association in women. In 
women, there was a logarithmic association for insulin with mace, inde-
pendent of age, alcohol consumption, and smoking (hr = 1.50 [95%CI 
1.17-1.91] per doubling of insulin, P=0.001). In men, for a similar mul-
tivariate model, there was a logarithmic association (hr = 1.13 [95%CI 
[0.97-1.32] per doubling of insulin, P=0.1). Further adjustment for com-
ponents of the insulin resistance syndrome weakened the association 
more in men than in women. With homa instead of insulin, results were 
essentially similar.
Conclusions
In parallel with diabetes, fasting hyperinsulinaemia reflecting insulin 
resistance in non-diabetic subjects is associated with an increased risk 
for cardiovascular disease, which is more pronounced in women than in 
men.
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Introduction
Cardiovascular disease (cvd) is a leading cause of death in both women 
and men. In general, women have a lower risk for cvd than men. It is, 
however, well known that diabetes is a stronger cvd risk factor in women 
than in men, thereby negating the female advantage with respect to cvd.1-3 
Whether insulin resistance is an underlying factor in this sex difference is 
unknown.
 Type 2 diabetes is often preceded by insulin resistance and develop-
ment of cardiovascular disease starts long before diabetes is diagnosed.4 
Fasting insulin concentrations are considered to mainly reflect compen-
satory hyperinsulinaemia and the degree of insulin resistance in non-
diabetic subjects.5 As such, fasting insulin has been shown to be a predic-
tor of cv events, independent of age, sex and body mass index, in three 
meta-analyses.6-8 Of the studies on fasting insulin as a predictor of cvd 
risk factor only few included women,6-8 so it is not known whether there 
is a sex difference for fasting insulin as a predictor of cv events.
 The aim of this study was to examine whether there is a sex difference 
in the association of fasting insulin concentrations with major adverse 
cardiovascular events (mace) in a non-diabetic population.
Methods
Study population and design
For this prospective study, we used data of the prevend study (Prevention 
of Renal and Vascular End-stage Disease). The prevend study is an ongo-
ing longitudinal cohort study based on the general population of the city 
of Groningen, the Netherlands, between the ages of 28 and 75 years. In 
brief, 8592 individuals completed the baseline survey (1997-1998). For the 
present study we first excluded subjects who had not explicitly stated to 
have been fasting for at least eight hours prior to baseline blood sampling 
(n=857 subjects). We then excluded subjects with diabetes according to 
ada guidelines (defined as a fasting plasma glucose ≥7.0 mmol/l or the use 
of anti-diabetic medication, n=298), subjects with a prior history of cvd 
(n=363), and finally we excluded those remaining subjects with missing val-
ues of insulin at baseline (n=168), eventually leaving 6916 subjects for pres-
ent analysis. The prevend study was approved by the institutional review 
board of our institution and is conducted in accordance with the guidelines 
of the declaration of Helsinki. All participants signed informed consent. 
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Follow-up and outcomes events
The primary endpoint of this analysis was Major Adverse Cardiovascular 
Events (mace). mace was defined as the combined endpoint of incident 
cardiovascular morbidity and mortality that occurred during the follow-
up of the study. Information (on hospitalisation) for cardiovascular 
morbidity was obtained from prismant, the Dutch national registry 
of hospital discharge diagnoses. Data on mortality were received from 
the municipal register, and cause of death was obtained by linking the 
number of the death certificate to the primary cause of death as coded by 
the Dutch Central Bureau of Statistics. Data were coded according to the 
International Classification of Diseases, 9th revision and the classification 
of interventions. mace was defined as the following; acute myocardial 
infarction (icd-code 410), acute and subacute ischemic heart disease (411), 
occlusion or stenosis of the precerebral (433) or cerebral arteries (434) and 
the following procedures: coronary artery bypass grafting or percutane-
ous transluminal coronary angioplasty, and other vascular interventions 
namely percutaneous transluminal angioplasty or bypass grafting of aorta 
and peripheral vessels. Survival time was defined as the period from the 
baseline survey to the date of a first major cardiovascular event. Subjects 
who did not develop mace were censored on December 31st 2005. In case 
a person had moved to an unknown destination, the date on which the 
person was removed from the municipal registry was used as censor date.
Measurements and definitions
Participants underwent two visits to the outpatient research unit for 
the baseline survey. All participants completed a questionnaire on 
demographics, cardiovascular disease history, smoking habits, alcohol 
consumption and medication use prior to their first visit. Height and 
weight were measured on the first visit and a fasting blood sample was 
drawn. Subjects were instructed to be fasting for at least 8 hours. During 
the first and second visit blood pressure was measured, in supine posi-
tion, every minute for 10 with an automatic device (Dinamap XL Model 
9300, Johnson-Johnson Medical, Tampa, FL). Blood pressure values are 
given as the mean of the last two recordings of both visits. Furthermore, 
information on medication use was substantiated with use of pharmacy-
dispensing data from all community pharmacies in the city of Groningen. 
This database has complete information on drug-use of approximately 
80% of subjects in the prevend study. 
 Diabetes was defined according to the guidelines of the American 
Diabetes Association as a fasting plasma glucose ≥7.0 mmol/L or the use of 
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antidiabetic medication. Impaired fasting glucose was defined as a fasting 
glucose >5.6 mmol/l and <7.0 mmol/l. Homeostasis Model Assessment 
(homa) was calculated as: [glucose (mmol/l) x insulin (μU/ml)] / 22.5]. 
Prior history of cvd at inclusion of the study was defined as self report of 
cerebrovascular accidents, coronary heart disease, or peripheral vascular 
disease requiring surgery.
Laboratory measurements
Insulin was measured with an AxSym® auto-analyzer (Abbott 
Diagnostics, Amstelveen, the Netherlands) with a threshold of 7 pmol/l 
and intra-assay and inter-assay coefficients of variation of 2.6 and 4.3% 
respectively. This assay has virtually no cross-reactivity with pro-insulin 
(0.016% at 106 pg/ml). The correction coefficient applied for calculation 
of homa from insulin concentrations is 1 μU/ml=6.00 pmol/l.9 Hdl cho-
lesterol, triglycerides, and glucose were measured by standard methods.
Statistical analysis
Analyses were performed using SPSS version 14.0 (SPSS Inc. Chicago IL, 
USA) and GraphPad Prism version 4.03 (GraphPad Software Inc. San 
Diego, CA, USA). Normally distributed values are presented as the mean 
(standard deviation), and a statistical difference was tested with a students 
t-test. Variables with a skewed distribution are presented as median 
[inter-quartile range], and a statistical difference was tested with a Mann-
Witney U test. A difference between categorical variables was tested 
using x-square test. Hazard ratio’s (hr) were reported with 95% confi-
dence interval [95%CI]. A two-sided P-value <0.05 indicated statistical 
significance. Interactions were considered significant at a P-value <0.1. 
 First, presence of a potential interaction between sex and fasting 
insulin for mace was investigated with Cox regression analyses. All vari-
ables did not violate the Cox-regression proportional hazard assump-
tion according to Schoenfeld residuals. Kaplan-Meier curves were made 
according to quartiles of fasting insulin and tested with Log-Rank test. 
 Fasting insulin was entered as a continuous variable in Cox-regression 
analyses. First, the crude model was adjusted for age and sex (model 1), 
and subsequently for smoking and alcohol consumption as these are 
considered confounders between the association of insulin and cardio-
vascular disease (model 2).10, 11 Finally, we further adjusted model 2 for 
waist circumference, hdl cholesterol, fasting triglycerides, systolic blood 
pressure, and fasting glucose (as components of what is considered the 
insulin resistance syndrome). Model 2 was first adjusted for each separate 
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component and then for all components combined (model 3). In a sensi-
tivity analysis those with impaired glucose tolerance were excluded. In 
a second sensitivity analysis homa was used instead of fasting insulin as 
measure of insulin resistance and all analyses were repeated
Results
Fasting insulin concentrations were lower in women than in men (54 [38-
77] pmol/l versus 57 [40-88] pmol/l, P<0.001) and also less women had 
impaired fasting glucose than men (5.8% vs 10.8%, P<0.001) (table 1). 
Both women and men were predominantly Caucasian (>95%). Women 
consumed less alcohol, had a lower bmi (25.8 ± 4.6 kg/m2 vs 26.2 ± 3.6 kg/
m2), a lower blood pressure (systolic 124 ± 21 mmHg vs 133 ± 18 mmHg), 
and lower triglycerides (1.0 [0.8-1.5] mmol/l vs 1.3 [0.9-1.8] mmol/l) 
with higher hdl cholesterol concentrations (1.5 ± 0.4 mmol/l vs 1.2 ± 0.3 
mmol/l) (all P<0.001). 
 During a follow-up of 7.5 [7.2-7.8] years, 98 cases of mace were 
recorded in women (incidence: 38 events per 10,000 person years). During 
a follow-up of 7.5 [6.9-7.8] years, 242 cases of mace were recorded in 
men (incidence: 106 events per 10,000 person years). In the exploratory 
Cox-regression analysis, there was a significant interaction between fast-
ing insulin concentrations and sex for mace, as indicated by a significant 
product-term of insulin and sex (ß= 1.006 [1.002-1.009], P=0.001), in a 
model with ß = 1.002 [1.001-1.004], P=0.01 for insulin (per pmol/l) and ß 
= 0.23 [0.16-0.34], P<0.001 for sex. We thus proceeded with the analyses 
separately in women and men.
 Kaplan Meier curves for quartiles of fasting insulin concentrations 
in women and men are shown in figure 1. Log Rank tests indicated that 
quartiles of fasting insulin concentrations were significantly associated 
with mace in women (P<0.001), while in men there was only a trend 
(P=0.1). In the 1st quartile of fasting insulin 12 (1.4%) women developed 
mace, but comparably in the 4th quartile 43 (4.7%) women developed 
mace (table 2). The age adjusted hr of the 4th versus the 1st quartile was 
2.30 [1.20-4.39], P=0.01. In men, the incidence of mace also increased with 
higher fasting insulin, but not as strongly as compared to women. In the 
1st  quartile, 47 (5.8%) men had mace, while in the 4th quartile 71 (8.7%) 
had mace, but the 4th quartile did not have significantly more mace 
when adjusted for age (hr: 1.11 [0.77-1.60], P=0.6). Because analyzing the 
data in quartiles is arbitrary and no established cut off points exist for 
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Figure 1.
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 Figure 1 
Kaplan-Meier curves for MACE in quartiles of fasting insulin and HOMA in 
women and men. 
Kaplan-Meier for mace in quartiles of fasting insulin and homa in women and men. Significance was tested 
with Log-rank test.  
In women fasting insulin concentration for the 1st quartile was <38 pmol/l (n=887), 2nd quartile 38-53 
pmol/l (n=916), 3rd quartile 53-77 pmol/l (n=910), and 4th quartile >77 pmol/l (n=913). In men fasting 
insulin concentration for the 1st quartile was <40 pmol/l (n=807), 2nd quartile 40-58 pmol/l (n=844), 3rd 
quartile 58-87 pmol/l (n=821), and 4th quartile >87 pmol/l (n=818). 
In women homa in the 1st quartile was <1.1l (n=906), 2nd quartile 1.1-1.5 (n=907), 3rd quartile 1.5-2.3 
(n=908), and 4th quartile >2.3 (n=905). In men homa in the 1st quartile was <1.2 (n=823), 2nd quartile 
1.2-1.7 (n=821), 3rd quartile 1.7-2.7 (n=824), and 4th quartile >2.7 (n=822). 
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table 1. Baseline characteristics by sex 
Women Men
n= 3626 3290 P-value































BMI, kg/m2 25.8±4.6 26.2±3.6 <0.001



















Glucose, mmol/l 4.6±0.6 4.9±0.6 <0.001
Impaired fasting glucose, n (%) 208 (5.8) 347 (10.6) <0.001
Insulin, pmol/l 54 [38-77] 57 [40-87] <0.001
HOMA 1.88±1.39 2.17±1.68 <0.001
Abbreviations: bmi: Body Mass Index, hdl: High Density Lipid, homa: Homeostasis Model Assessment
Normally distributed variables are given as mean (standard deviation). Variables with a skewed distribution are 
presented as median [inter-quartile range]. Categorical variables are presented as number (percentage). Differences 
between men and women were tested by t-test for variables with a normal distribution, by Mann-Withney U-test 
for variables with a skewed distribution and by Chi-square test for categorical variables






































































































































































































































































































































































































































































































































































































































































































































































































































































* Incidence per 10.000 person years
Median and range is given of fasting insulin and HOMA
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fasting insulin, we further analyzed our data with insulin as a continuous 
variable.
 In women, every doubling of fasting insulin increased the risk of 
mace by 83% (P<0.001), which was reduced to 50% after adjustment for 
age, alcohol consumption, and smoking (P=0.002) (model 2, table 3). In 
women, with separate adjustment for components of the insulin resis-
tance syndrome other than bmi or waist circumference, insulin remained 
significantly associated with mace. After adjustment for bmi or waist cir-
cumference the association weakened to borderline significance (P=0.09 
and P=0.1 respectively). 
 In men, every doubling of fasting insulin increased the risk of mace 
by 20% (P= 0.02), which became non-significant after adjustment for 
age (P=0.5, Crude model and model 1, table 3). The association was 
confounded by alcohol consumption and smoking, as the hr slightly 
increased with adjustment in model 2. Fasting insulin was not associated 
with further adjustment of each separate component (models 2) of the 
insulin resistance syndrome or all components together (model 3, table 3). 
 In a sensitivity analysis we excluded those with impaired fasting glu-
cose, which left 3418 women with 80 cases of mace and 2943 men with 
206 cases of mace for analysis. The interaction between fasting insulin 
and sex remained significant (P=0.008 for the product term of insulin and 
sex). Results changed little as there was a logarithmic association between 
fasting insulin and mace in women the hazard ratio was 1.46 [1.11-1.92], 
per doubling of fasting insulin (P=0.007), but not significantly in men with 
a hazard ratio of 1.13 [0.96-1.33], per doubling of fasting insulin (P=0.1) 
after adjusment of age, alcohol consumption and smoking. Both in men 
and in women fasting insulin was not associated with mace independent 
of other factors of the insulin resistance syndrome in women, hr was 1.17 
[0.84-1.63] per doubling of fasting insulin, P=0.4 and in men hr was 0.94 
[0.77-1.15] per doubling of fasting insulin, P=0.6). All results presented 
were also analyzed with homa instead of fasting insulin, which revealed 
similar results as the primary analyses (see table 2, table 3, and figure 1).
Discussion
In this study, we found that higher fasting insulin concentrations had a 
stronger and steeper association with more cvd events in women than in 
men, although this was not independent of components of what is consid-
ered the insulin resistance syndrome. The greater susceptibility of insulin 
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resistant women than men for cvd events could perhaps be an underlying 
reason why diabetes negates the female advantage for less cvd.
 In our study, women in the 4th quartile versus the 1st quartile of fast-
ing insulin, had an age adjusted hr of 2.30 (P=0.01) for mace. In men 
this hr was 1.11 (P=0.6). In women the association was also logarith-
mic, indicating a steep increase in the risk with higher insulin levels. In 
women, it seems that obesity underlies the association between insulin 
and mace because bmi and waist circumference made the association 
between insulin and mace non-significant (P=0.08). Dyslipidaemia and 
hypertension most likely do not underlie the association because the 
association remained after adjustment for hdl-cholesterol, triglycer-
ides, and systolic blood pressure. Similarly in both women and men, all 
components when entered together made the association non-significant. 
Especially in women, non-significance most likely indicates a statistical 
over-correction, and not that increased insulin concentrations (reflecting 
of insulin resistance) do not increase cvd risk. Furthermore, these results 
are not necessarily contradictory to earlier studies, because not all studies 
reported independent affects of fasting insulin for cvd events.6-8
 To date approximately twenty-five prospective studies have been 
published whether fasting insulin concentrations predict cvd in men, but 
few studies have included women.6-8 Results from the aric study reported 
a greater risk for coronary heart disease (chd) associated with fasting 
insulin in women compared to men. In 13,466 non-diabetic people, free 
of baseline chd, 209 men and 96 women developed chd with an adjusted 
relative risk of 2.8 (P=0.02) in women, but 0.9 (P=0.6) in men.12 However, 
this study was performed with a non-specific insulin assay, making it pos-
sible that effects are the consequence of pro-insulin or pro-insulin like 
molecules rather than insulin itself, as proinsulin has been shown to be 
associated with cvd independent of fasting insulin concentrations.13, 14 
A recent meta-analyses suggested that women had a greater risk for 
development of coronary heart disease in association with fasting insulin 
concentrations, but this could not be formally tested because of a lack of 
power.8 It is indicative of the little data currently available in women that 
the results of this recent meta-analysis were based on 2427 cases in men 
and only 155 cases in women, which is a comparable number of cases as 
in this present study.8 In the San Antonio Heart Study, homa and fasting 
insulin a gender interaction was not found for (self reported) cvd events, 
possibly because it concerned less subjects (n=2569) and less events 
(n=187) compared to the present study.15 In conclusion, data in woman 
are sparse, and not conclusive, though a recent meta-analysis suggested 
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that insulin is a greater cvd risk factor in women than in men.8
 It is debated whether high insulin levels by themselves lead to cardio-
vascular disease.10, 11 The consensus is that a causal relationship between 
insulin and cvd is not likely, but rather between insulin resistance and 
cvd.16 Insulin resistance leads to compensatory hyperinsulinaemia 
and increased fasting insulin concentrations, which are associated with 
increased cvd risk.5, 6 Two studies have measured insulin resistance per se 
in smaller cohorts, and both indicate that insulin resistance is associated 
with cvd risk.17, 18 Unfortunately, a specific sex difference could not,17 or 
was not investigated.18 It has also been suggested that the associations 
found with fasting insulin, as measure of insulin resistance, were due to an 
association between insulin and smoking related cvd, or greater mortal-
ity due to underweight and greater alcohol consumption as an indication 
of overall poor health or malignancies.10, 11 In our regression models we 
show that smoking, alcohol consumption and by design we show that 
cvd history (as persons with known cvd were excluded) do not underlie 
the association between insulin and mace in women. 
 The hallmark of diabetes is hyperglycaemia, which results from 
ß-cell dysfunction. In type 1 diabetes, a disease in which primarily ß-cell 
failure occurs and not insulin resistance, women also have a greater cvd 
risk than men, as shown in several studies.19, 20 This could indicate that 
ß-cell dysfunction plays a role in the sex difference of cvd in type 2 dia-
betes. However, in the studies in type 1 diabetes it is unknown whether 
hyperglycaemia or ß-cell dysfunction account for the sex difference.19, 20 
Moreover, insulin resistance increases cvd risk in type 1 diabetes, and a 
sex difference with insulin resistance for coronary artery calcifications has 
been shown.21, 22 In non-diabetic persons, elevated pro-insulin levels can 
be attributed to ß-cell dysfunction, and fasting pro-insulin is a stronger 
predictor for cvd than fasting insulin.13, 14 However, in the Hoorn study, 
homeostasis model assessment of ß-cells (homa-B), and the pro-insulin 
to insulin ratio (a better marker of ß-cell dysfunction than pro-insulin) 
did not predict cvd mortality, indicating that pro-insulin itself could be 
atherogenic, and that the role of ß-cell dysfunction in cvd is uncertain.14 
 Whether hyperglycaemia increases cvd risk in non-diabetic subjects is 
controversial. Meta-analyses show an association between fasting glucose 
and cvd in non-diabetic subjects,23, 24 but not all studies indicate an inde-
pendent association, thus the topic remains somewhat controversial.25, 26 
Importantly, meta-analyses indicating an independent effect of glucose 
did not include measures of insulin resistance, whilst the meta-analyses 
of fasting insulin did include glucose.6-8 The notion that insulin resistance 
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is more important than elevated glucose levels in non-diabetic women at 
least is corroborated by a recent study that showed that fasting insulin 
was a stronger predictor of coronary heart disease than fasting glucose 
or glycated haemoglobin.27 In summary, ß-cell dysfunction and hyper-
glycaemia could well play a role in the sex difference of cvd risk in non-
diabetic persons, but there is plausible contradictory data against this. 
 A limitation of the study is that insulin resistance was not specifically 
measured using a hyperinsulinaemic euglycaemic clamp. However, this 
is not easily feasible in such a large population study. We did corroborate 
our results with the homa index, which gave essentially similar results as 
with fasting insulin. Secondly, this study is limited to Caucasian popula-
tions, and results can not be directly extrapolated to other populations. 
An important strength of this study is that we used a highly specific insu-
lin assay, i.e. with very little cross-reactivity with pro-insulin, thereby 
attributing the current findings solely to insulin and not to pro-insulin or 
pro-insulin like molecules. Importantly, we excluded those with known 
cvd, thus the effects of insulin are not diluted or confounded by prevalent 
cvd. Finally, results remained essentially similar after exclusion of those 
with impaired fasting glucose, indicating that diabetic persons who were 
perhaps misclassified as non-diabetic also do not confound our results.
 The increased cvd risk in women with hyperinsulinaemia in women 
should perhaps warrant greater attention for treatment in women. This 
could be important because treatment of modifiable cvd risk shows a 
sex disparity in which women often receive less treatment.28, 29 Perhaps, 
women could benefit more from treatment aiming at improvement 
of insulin sensitivity than men by weight loss or physical exercise. 
Intriguingly, in healthy young women muscle can utilize more glucose 
per kilogram than in healthy males.30 It should furthermore be noted that 
many women in our study may have been around menopause. Although 
we found no effect-modification by age for the effect of insulin, it can 
not be excluded that estrogenic state in women plays a role, and that the 
difference between men and women is mainly determined by lack of 
oestrogen in postmenopausal women.
 In conclusion, this study shows that higher fasting insulin concentra-
tions assessed with a specific assay are more strongly associated with an 
increased risk for cardiovascular disease in women than in men, although 
the effect of insulin was not independent of variables related to insulin 
resistance. Obesity was the most important factor in women negating the 
association between insulin and cardiovascular disease.
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